Theflyonthewall.com is Wall Street's specialist in breaking equity news. Veteran traders build a proprietary feed of news that's faster and more relevant than any other source. Try us for free and discover for yourself.
Theflyonthewall.com is Wall Street's specialist in breaking equity news. Veteran traders build a proprietary feed of news that's faster and more relevant than any other source. Try us for free and discover for yourself.
Oppenheimer gave the Biotechnology industry some bad news as it announced a downgrade on one of its stocks.
Cadence Pharmaceuticals Inc. (CADX) [Chart - News - Analysis] was downgraded from Outperform » Perform on 11/16/2009---a negative sign for the stock that investors will have to endure. FYI, Oppenheimer uses the following rating scale when analyzing stocks: Outperform, Perform, Underperform.
{loadposition link_newslink1}
{loadposition livevideopromo}
{loadposition contentad}
Cadence Pharmaceuticals Inc. has an average analyst recommendation score of 1.8 and competes for investment dollars with Celgene Corporation (CELG) [Chart - News - Analysis] and Amgen Inc. (AMGN) [Chart - News - Analysis]---two other stocks in the Biotechnology industry that have average analyst recommendation scores of 2.0 and 1.9 respectively.
Analyst recommendations are averaged and scored using the following rating scale:
- 1.0 = Strong Buy
- 2.0 = Buy
- 3.0 = Hold
- 4.0 = Sell
- 5.0 = Strong Sell
Why are Upgrades and Initiations Good and Downgrades Bad?
One event that is almost certain to get a reaction from Wall Street is an analyst upgrade or downgrade. Everyone is looking for an edge in the stock market, and quite often, traders turn to stock analysts to get that edge.
Upgrades and coverage initiations are typically good for stocks because they show that analysts either believe that the stock is going to perform better in the future or that the stock is worth covering and providing analysis on.
Downgrades are typically bad for stocks because they show that analysts believe that the stock is going to perform worse in the future.
A stock analysts is a person---typically employed by a large bank, investment firm or analysis company---who devotes his/her life to learning and making predictions about a company and its future performance.
Stock analysts sift through company reports and filings, talk to company management, probe customers and competitors and basically do whatever they can to find out if a company is healthy and growing or sick and shrinking. Because this is incredibly demanding work, stock analysts typically only monitor one or two companies at a time.
Biotech investors interested in seeing more details about these companies and a full list of their related stories can do so by typing the stock ticker symbol into the Stock Quotes box on the right side of the page.SunLink Health Systems, Inc. (NYSE:SSY) announced earnings from continuing operations for its fiscal quarter ended September 30, 2009 of $549,000, or $0.07 per fully diluted share, compared to a loss from continuing operations of $603,000, or $0.08 per fully diluted share, for the quarter ended September 30, 2008.Enzo Biochem Inc. (NYSE:ENZ) announced today that David Goldberg, Vice President, Corporate Development, will speak on the Company’s extensive oral immune regulation platform at the Windhover TA Partnerships 2009 conference in Boston, MA, on Wednesday, November 18, 2009, where Enzo’s EGS21, an orally administered beta glucosylceramide formulation, now undergoing clinical study, was named one of this year’s “top 10 inflammatory/autoimmune projects to watch.”Pro-Pharmaceuticals, Inc. (OTCBB: PRWP), a developer of galectin-targeted, carbohydrate therapeutic compounds to treat cancer and fibrosis, today reported its financial results for the third quarter and first nine months of fiscal 2009.Oculus Innovative Sciences, Inc. (NASDAQ:OCLS), a biopharmaceutical company that develops, manufactures and markets a family of products based upon the Microcyn® Technology platform, which is intended to treat chronic and acute wounds, today announced that its development partners, Bayer Animal Health divisions in China and Taiwan, recently secured regulatory approvals in both those countries to develop and market Microcyn-based Vetericyn™ products for their respective animal healthcare markets.Orthovita, Inc. (NASDAQ: VITA), an orthobiologics and biosurgery company, announced today that it will present at the Lazard Capital Markets 6th Annual Healthcare Conference in New York City.Ore Pharmaceutical Holdings Inc. (NASDAQ:ORXE) today reported financial results and provided an operational update for the third quarter ended September 30, 2009.China-Biotics, Inc. (Nasdaq: CHBT) ("China-Biotics," "the Company"), a leading Chinese firm specializing in the research, development, manufacture, marketing and distribution of probiotics dietary supplements, today announced it will host a conference call at 11:00 a.m. EST on Tuesday, November 17, 2009, to discuss the Company's financial results for the second quarter of its 2010 fiscal year.NovaBay Pharmaceuticals, Inc. (NYSE Amex: NBY), a clinical-stage biopharmaceutical company developing first-in-class anti-infective products for the treatment and prevention of a wide range of infections, today reported financial results for the third quarter ended September 30, 2009.Exelixis, Inc. (Nasdaq:EXEL) announced today that Frank Karbe, the company’s executive vice president and chief financial officer, will present at Lazard’s 6th Annual Healthcare Conference at 11:00 a.m. EST / 8:00 a.m. PST on Wednesday, November 18, 2009 in New York.Columbia Laboratories, Inc. (Nasdaq: CBRX) today commented that nothing fundamental in the Company’s operations has changed to cause the current market activity in its Common Stock.Talecris Biotherapeutics (Nasdaq: TLCR) and N.C. Gov. Bev Perdue jointly announced today that the company will expand its manufacturing facilities in Clayton, creating 259 new jobs over the next seven years.PanGenex Corporation (Pink Sheets:PGCX), a global nutraceutical and dietary supplement manufacturer and marketer, is pleased to announce today that two of the nation's leading interventional cardiologists, Dr. Steven Yakubov and Dr. Mark Turco, have joined the Company's Scientific Advisory Board.Celgene Corporation (NASDAQ: CELG) today announced its presentation at the Lazard Capital Markets 6th Annual Healthcare Conference on Tuesday, November 17, 2009 at 1:40 p.m. ET will be webcast live and will be available in the investor relations section of the company’s Web site at www.celgene.com.Genzyme Corp. (Nasdaq:GENZ) announced today that it has issued letters to U.S. healthcare providers regarding its enzyme replacement products Cerezyme® (miglucerase for injection), Fabrazyme® (agalsidase beta), Myozyme® (alglucosidase alfa), Aldurazyme® (laronidase), as well as Thyrogen® (thyrotropin alfa for injection), filled at its Allston Landing manufacturing facility.King Pharmaceuticals, Inc. (NYSE:KG) today announced plans to present at the Lazard Capital Markets 6th Annual Healthcare Conference on Wednesday, November 18, 2009, at 2:15 pm EST, at the St. Regis Hotel in New York, New York.MedaSorb Technologies Corporation (OTCBB:MSBT) and its wholly-owned subsidiary, CytoSorbents, Inc., today announced the filing of Q3 2009 financial results as reported in its Form 10-Q with the SEC.
by Marc Lichtenfeld, Healthcare Expert
Wednesday, November 11, 2009: Issue #1135
Investing in the biotech sector can be risky – no doubt about that.
But you know what? There are a lot of ways to make money from biotech stocks, too. If you know what to look for, that is.
Two obvious examples include:
Picking the company [...]
Franklin Biotechnology Discovery A (MAPTX) seeks capital appreciation by primarily investing in securities of biotechnology companies and discovery research firms.
This non-diversified fund may invest a substantial portion of assets in equity securities of smaller capitalization companies with a market capitalization of less than $1.5 billion.
Gilead Sciences Inc. (GILD), Celgene Corp. (CELG) and Genzyme Corp. (GENZ) [...]
Dr Stock Pick HOT News & Alerts!
_________________________________________
FREE Daily Stock Alerts From DrStockPick.com
_________________________________________
Wednesday November 11, 2009
DrStockPick.com Stock Report!
PWRM, CELG
**************************************************************
PWRM, Power 3 Medical Products Inc, PWRM.OB
Power3 Medical Products, Inc. is a leading bio-medical company engaged in the commercialization of neurodegenerative disease and cancer biomarkers, pathways, and mechanisms of diseases through the development of diagnostic tests and drug [...]
AN IDEA FOR A SLOW DAY
If you are a small-cap or micro-cap investor that takes the time to conduct proper research and due diligence into finding your next great investment, than you will be extremely happy to read
this article from The Motley Fool.
Why? Of the 10 best performing stocks over the past 10 years, 9 of them began their runs as companies capitalized at less than $200 million. I took the time to do some math and calculated the following astonishing facts:
Their average market cap is a mere $110 million.
If you backout the largest company in the group at the time, the average market cap falls to 64.7 million
3 companies had a market cap of $10 million or less - as low as $3 million
You would expect to see names like Dell, Apple, Starbucks, etc. but they are nowhere to be found on the list. Nope, the best performing stocks started out as obscure and ignored little companies that received no attention of any kind from analysts and brokers.
There is a great lesson to be learned here. Search for companies that have achieved market acceptance for their innovative products and services, have a solid management team, reasonable share structure, a good investor relations firm (had to say it and are relatively ignored by the “experts”.
At CFRN WE’RE finding great little companies and telling our listeners about it.
Hopefully, one our companies can make this list in the next 10 years. In the meantime, here is the current list - see any names that you recognize and may have skipped over? Company 1997 Market Cap Return, 1997-2006 Hansen Natural HANS $10 million 25,538% Chico’s (NYSE: CHS) $34 million 8,773% American Eagle (Nasdaq: AEO) $78 million 7,884% Daktronics (Nasdaq: DAKT) $17 million 7,328% Celgene (Nasdaq: CELG) $111 million 6,118% 4 Kids Entertainment $3 million 5,447% NVR $191 million 4,871% Comtech Telecommunications $7 million 4,653% Best Buy (NYSE: BBY) $460 million 4,082% Frontier Oil (NYSE: FTO) $85 million 3,616%
Both the Dow and Nasdaq were in fine form Thursday as they surged higher with gusto. Stevie Wallstreet breaks the action down and what key levels of support to key off going forward. Also, (GOOG) has earnings coming up on the 31st - does it make for a good straddle? Stevie gives you the 411 and he shares his thoughts on what sentiment is telling you. Finally, he checks out the charts of (AAPL), (HAL), (CELG), (DP), (GS), (LEH), (LM), and (FDG).
All News |
Breaking News |
Featured Stories